Equity Real Estate Investment Trusts (REITs)

Veris Residential

Veris Residential released FY2026 Q1 earnings on April 22 (EST), actual revenue USD 0 (forecast USD 70.76 M), actual EPS USD 0 (forecast USD -0.03)

Veris Residential released FY2025 earnings on February 23 After-Market EST, actual revenue USD 293.29 M (forecast USD 286.07 M), actual EPS USD 0.8059 (forecast USD 0.6711)

Veris Residential released FY2025 Q4 earnings on February 23 After-Market EST, actual revenue USD 71.16 M (forecast USD 70.92 M), actual EPS USD -0.0021 (forecast USD -0.0712)

Veris Residential to be Acquired in All-Cash Deal for About $3.4 Billion

Veris Residential to Release FY2025 Q4 Earnings on February 24 After-Market EST, Forecast Revenue USD 70.92 M, EPS USD -0.0712

Galan Analyst's Real Estate Stock Ratings Data

Truist Financial Maintains Hold Rating on Veris Residential

Veris Residential released FY2025 Q3 earnings on October 22 After-Market EST, actual revenue USD 73.88 M (forecast USD 73.74 M), actual EPS USD 0.8015 (forecast USD -0.0661)

Veris Residential released FY2025 9 Months Earnings on October 22 After-Market EST, with actual revenue of USD 148.11M and EPS of USD 0.0015

Veris Residential to release FY2025 Q3 earnings on October 22 After-Market EST, forecast revenue USD 73.74 M, EPS USD -0.0661

Veris Residential released FY2025 Semi-Annual earnings on July 23 After-Market EST, actual revenue USD 147.75 M, actual EPS USD 0.0021

Veris Residential released FY2025 Q2 earnings on July 23 After-Market (EST), actual revenue USD 76.35 M (forecast USD 71.07 M), actual EPS USD 0.1164 (forecast USD -0.0972)

Veris Residential to Release FY2025 Q2 Earnings on July 23 After-Market EST, Forecast Revenue USD 68.8 M, EPS USD -0.0972

Veris Residential Amends Credit Facility and Sells Signature Place

Veris Residential Reports Q2 2025 Earnings

Veris Residential Inc. Chief Investment Officer Jeffrey Turkanis to Resign

GAMMA Investing LLC Significantly Increases Holdings in Veris Residential

Veris Residential Inc. Announces $0.08 Dividend Per Share

Truist Securities Maintains Veris Residential Rating, Target Price Cut to $16

Veris Residential released FY2025 Q1 earnings on April 23 After-Market EST, actual revenue USD 71.75 M (forecast USD 69.24 M), actual EPS USD -0.1149 (forecast USD -0.1014)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Veris Residential is facing shareholder scrutiny over its merger disclosures following an all-cash acquisition agreement at $19 per share by Affinius Capital Advisors and Vista Hill Partners. Amid lawsuits challenging the adequacy of disclosures, the company provided detailed financial information to mitigate litigation risks. The special meeting is set for May 21, 2026, with analysts rating VRE stock as a Hold at a $19 price target, reflecting mixed sentiments due to the acquisition and market conditions.

Tip Ranks

JPMorgan Chase

Morgan Stanley

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Veris Residential Faces Shareholder Scrutiny Over Merger Disclosures

XOMA

Halper Sadeh LLC is investigating XOMA, Organon & Co., and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders in proposed transactions. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on XOMA's sale for $39.00 per share, Organon's sale for $14.00 per share, and Veris's sale for $19.00 per share, with the firm seeking increased consideration and disclosures on behalf of shareholders.

prnewswire

XOMA Royalty

Organon

Ligand Pharmac-B

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

Veris Residential, Inc. (VRE) faces potential litigation risks that may delay its merger and increase legal costs. An observer warns that ongoing or future lawsuits could distract management from key operations and lead to significant expenses. If plaintiffs successfully seek an injunction, it could block or postpone the merger, creating uncertainty for investors. The average stock price target for VRE is $20.00, indicating a 5.71% upside potential.

Potential Litigation Threatens to Delay Veris Residential Merger and Increase Legal Costs

NDAQ

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Teleflex

Nasdaq

Teleflex (TFX) Q4 2024 Earnings Transcript

Earnings Watch

Veris Residential | 10-Q: FY2026 Q1 Revenue: USD 70.1 M

APLS

EHAB

Halper Sadeh LLC is investigating Clear Channel Outdoor Holdings, Enhabit, Apellis Pharmaceuticals, and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. They are encouraging shareholders to discuss their rights and options regarding the proposed sales of these companies, which include cash offers and contingent value rights. Halper Sadeh LLC aims to seek increased consideration and other benefits for shareholders.

Clear Channel Outdoor

Apellis Pharma

Enhabit Home Health & Hospice

Biogen

18:59 ETAre CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC is investigating Veris Residential, Inc. (NYSE: VRE), Select Medical Holdings Corporation (NYSE: SEM), and Two Harbors Investment Corp. (NYSE: TWO) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. Shareholders are encouraged to contact the firm to discuss their rights and options regarding the proposed transactions, which may limit competing offers. Halper Sadeh LLC operates on a contingent fee basis, ensuring no upfront legal costs for clients.

Two Harbors Investment

Select Medical

UWM HLDGS CORP C/WTS 21/01/2026 (TO PUR COM)

12:55 ETAre VRE, SEM, TWO Obtaining Fair Deals for their Shareholders?

REET

SCHH

SRET

XLRE

Montreal-area home sales increased by 2.2% year-over-year in March, breaking a four-month decline. A total of 5,045 residential properties were sold, although this remains below the average for March over the past decade. Home prices rose across all categories, with single-family homes seeing a 6.9% increase in median price to $652,250. New listings rose by 11.2% to 8,574, and total inventory increased by 12.7% to 19,952 units. The sales uptick is seen as a positive sign for the Montreal real estate market amid broader challenges in Canada's housing sector.

Veris Residential(VRE.US)